艾美赛珠单抗: 一种F10抑制剂、factor IXa抑制剂药物,由Chugai Pharmaceutical Co., Ltd. (Chugai Pharmaceutical Co., Ltd.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: F10抑制剂(凝血因子X抑制剂),factor IXa抑制剂(激活型凝血因子IX抑制剂),治疗领
Prevent Adverse Drug Events Today Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more Pharmacodynamics Risankizumab works to suppress the inflammatory effects of interleukin (IL)-23. It inhibits th...
AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI®, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] startin...
The trial also met all key secondary endpoints confirming rapid onset of action on itch as early as week 4 (41.1% compared to 6.3% in the placebo group; p<0.0001), and improvements in itch and skin lesions were observed up to week 24. Nemolizumab was well tolerated, and its safety pr...
The trial also met all key secondary endpoints confirming rapid onset of action on itch as early as week 4 (41.1% compared to 6.3% in the placebo group; p<0.0001), and improvements in itch and skin lesions were observed up to week 24. Nemolizumab was well tolerated, and its safety pr...
, June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial (NCT04540497) evaluating ...
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns Not Available Not Yet Recruiting Not Available Neuromyelitis Optica Spectrum Disorders (NMOSD) 1 somesta...
“Today’s BE SURE findings are consistent with the positive results we recently announced for both BE VIVID and BE READY,” said Iris Loew-Friedrich, head of drug development and chief medical officer, UCB. “UCB is committed to addressing the critical unmet needs of adult patients with ...
today announced the presentation of updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab, a humanized anti-PD-1 monoclonal antibody, in combination with chemotherapy versus chemotherapy plus ...
With a robust clinical trial program, AbbVie is committed to cutting-edge research to drive exciting developments in inflammatory bowel diseases (IBD), like ulcerative colitis and Crohn's disease. By innovating, learning and adapting, ...